Shanghai Haohai Biological Technology Co (SHSE:688366) Total Assets: ¥6,666 Mil (As of Mar. 2026)


SHSE:688366 Shanghai Haohai Biological Technology Co Ltd SHSE:688366
73 GF Score
Price ¥32.03
GF Value ¥47.40
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is Shanghai Haohai Biological Technology Co Total Assets?

Shanghai Haohai Biological Technology Co SHSE:688366 +6.17% 73 Total Assets is ¥6,666 Mil as of Mar. 2026. GuruFocus rates SHSE:688366 with a GF Score™ of 73/100 and a GF Value™ of ¥47.40 (Significantly Undervalued). The stock has 5 warning signs investors should review.

Shanghai Haohai Biological Technology Co's Total Assets for the quarter that ended in Mar. 2026 was ¥6,666 Mil.

During the past 12 months, Shanghai Haohai Biological Technology Co's average Total Assets Growth Rate was 2.70% per year. During the past 3 years, the average Total Assets Growth Rate was -1.50% per year. During the past 5 years, the average Total Assets Growth Rate was 2.40% per year. During the past 10 years, the average Total Assets Growth Rate was 15.00% per year.

During the past 12 years, Shanghai Haohai Biological Technology Co's highest 3-Year average Total Assets Growth Rate was 63.90%. The lowest was -1.70%. And the median was 13.30%.

Total Assets is connected with ROA %. Shanghai Haohai Biological Technology Co's annualized ROA % for the quarter that ended in Mar. 2026 was 4.40%. Total Assets is also linked to Revenue through Asset Turnover. Shanghai Haohai Biological Technology Co's Asset Turnover for the quarter that ended in Mar. 2026 was 0.09.


Shanghai Haohai Biological Technology Co  (SHSE:688366) Total Assets Explanation

Total Assets is connected with ROA %.

Shanghai Haohai Biological Technology Co's annualized ROA % for the quarter that ended in Mar. 2026 is

ROA %=Net Income (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=294.236/( (6720.063+6666.309)/ 2 )
=294.236/6693.186
=4.40 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Shanghai Haohai Biological Technology Co's Asset Turnover for the quarter that ended in Mar. 2026 is

Asset Turnover
=Revenue (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=571.435/( (6720.063+6666.309)/ 2 )
=571.435/6693.186
=0.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Shanghai Haohai Biological Technology Co Total Assets Related Terms


Shanghai Haohai Biological Technology Co Total Assets Historical Data

* Premium members only.

The historical data trend for Shanghai Haohai Biological Technology Co's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai Haohai Biological Technology Co Total Assets Chart

Shanghai Haohai Biological Technology Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6,950.36 6,892.40 7,105.50 7,121.39 6,720.06

Shanghai Haohai Biological Technology Co Quarterly Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Jun25 Sep25 Dec25 Mar26
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7,121.39 7,185.80 7,118.07 6,720.06 6,666.31
SHSE:688366
73GF Score
Shanghai Haohai Biological Technology Co Ltd SHSE:688366
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shanghai Haohai Biological Technology Co Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Shanghai Haohai Biological Technology Co's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (A: Dec. 2025 )+Total Liabilities (A: Dec. 2025 )
=5604.503+1115.56
=6,720

Shanghai Haohai Biological Technology Co's Total Assets for the quarter that ended in Mar. 2026 is calculated as

Total Assets=Total Equity (Q: Mar. 2026 )+Total Liabilities (Q: Mar. 2026 )
=5600.451+1065.858
=6,666

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of ¥6,666 Mil mean?
Shanghai Haohai Biological Technology Co (SHSE:688366) has a Total Assets of ¥6,666 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Shanghai Haohai Biological Technology Co and its competitors.
Is Shanghai Haohai Biological Technology Co's Total Assets too high?
Shanghai Haohai Biological Technology Co's current Total Assets is ¥6,666 Mil. Overall, Shanghai Haohai Biological Technology Co has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Haohai Biological Technology Co's Total Assets compare to VRTX and REGN?
Shanghai Haohai Biological Technology Co's Total Assets of ¥6,666 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Shanghai Haohai Biological Technology Co and its competitors. Shanghai Haohai Biological Technology Co's current Total Assets is ¥6,666 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Haohai Biological Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Haohai Biological Technology Co (SHSE:688366) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥47.40, compared to a current price of ¥32.03 — trading 32.4% below its estimated fair value. The current Total Assets is ¥6,666 Mil. Shanghai Haohai Biological Technology Co's overall GF Score™ is 73/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Shanghai Haohai Biological Technology Co (SHSE:688366), the current Total Assets is ¥6,666 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shanghai Haohai Biological Technology Co (SHSE:688366) Overvalued in 2026?

Based on GuruFocus' analysis, Shanghai Haohai Biological Technology Co stock appears to be undervalued. The current stock price of ¥32.03 is trading 32.4% below its estimated GF Value™ of ¥47.40. GuruFocus considers Shanghai Haohai Biological Technology Co to be Significantly Undervalued.

Key valuation signals for SHSE:688366:

  • Total Assets: ¥6,666 Mil
  • GF Value™: ¥47.40 vs. price of ¥32.03 (32.4% below fair value)
  • GF Score™: 73/100 with 5 warning signs

No single metric tells the full story. See the SHSE:688366 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Shanghai Haohai Biological Technology Co Business Description

Other Exchanges 06826:Hong Kong5HB:Germany
Address No. 1386 Hongqiao Road, 23rd Floor, WenGuang Plaza, Changning District, Shanghai, CHN
Shanghai Haohai Biological Technology Co Ltd is engaged in the manufacturing and sale of biologicals, medical hyaluronate, and ophthalmology products. The Company's operating activities are related to a single operating segment, which is the manufacture and sale of biologicals, medical hyaluronate, and intraocular lenses, research and development of biological engineering and pharmaceutical products, and the provision of related services. Its products are categorized into four types, comprising ophthalmology, medical aesthetics, orthopedics, and anti-adhesion. Geographically, it has operations in Mainland China, which is the key revenue driver, the United States, the United Kingdom, and other countries.
73GF Score

Get the complete analysis for SHSE:688366

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥32.03
Price
¥47.40
GF Value